29816-01-1

Basic information

• Product Name: GLYCYL-SARCOSINE
• Synonyms: H-GLY-SAR-OH;GLYCYL-SARCOSINE;GLY-SAR;N-glycylsarcosine;2-[N-(2-Aminoacetyl)-N-methylamino]acetic acid;Gly-N-methyl-Gly-OH;Gly-Sar-OH;N-Glycyl-N-methylglycine
• CAS NO: 29816-01-1
• Molecular Formula: C₅H₁₀N₂O₃
• Molecular Weight: 146.14
• EINECS: 249-875-2
• Mol File: 29816-01-1.mol
• Article Data: 2

Chemical Properties

• Melting Point: 198-202 °C (dec.)
• Boiling Point: 333.5°Cat760mmHg
• Flash Point: 155.5°C
• Appearance: /
• Density: 1.284g/cm³
• Vapor Pressure: 2.6E-05mmHg at 25°C
• Refractive Index: 1.51
• Storage Temp.: −20°C
• PKA: pK1:2.98(＋1);pK2:8.55(0) (25°C,μ=0.1)
• BRN: 1768450
• CAS DataBase Reference: GLYCYL-SARCOSINE(CAS DataBase Reference)
• NIST Chemistry Reference: GLYCYL-SARCOSINE(29816-01-1)
• EPA Substance Registry System: GLYCYL-SARCOSINE(29816-01-1)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 29816-01-1(Hazardous Substances Data)

Usage

Chemical Properties

White powder

InChI:InChI=1/C5H10N2O3/c1-7(3-5(9)10)4(8)2-6/h2-3,6H2,1H3,(H,9,10)

Upstream product

• 65332-01-6 methyl N-(2-chloroacetyl)glycine 
• 7801-91-4 Z-Gly-Sar-OH 

Downstream Products

• 5625-52-5 1-methylpiperazin-2,5-dione 
• 562814-60-2 3,6-dihydro-1-methyl-5-methylthiopyrazin-2(1H)-one 
• 562814-58-8 1-methylpiperazin-2,5-dithione 
• 562814-59-9 1-methyl-5-thioxopiperazin-2-one 
• 562814-61-3 1-methyl-5-cyanoiminopiperazin-2-one 
• 133498-97-2 t-BuOCO-Gly-Sar-OH 
• 1515606-29-7 C₅₆H₈₀N₁₀O₁₇ 
• 1574776-16-1 C₆₁H₈₈N₁₀O₁₉ 
• 1515605-87-4 C₃₁H₄₅N₅O₉*ClH 
• 1515605-81-8 C₄₃H₅₇N₅O₁₃S 
• 1515606-24-2 N-Cbz-D-Ser[N-Boc-N-Me-L-Val]-(S)-β-L-triisopropylsilyloxy-Pip-Gly-Sar-OH 
• 1515606-23-1 N-Cbz-D-Ser[N-Me-Val]-(S)-β-L-triisopropylsilyloxy-Pip-Gly-Sar allyl ester 
• 100940-65-6 sandramycin 
• 1515605-40-9 (N-Cbz-D-Ser-L-Pip-Gly-Sar-N-Me-Val)₂ 

Relevant articles and documents

DIPEPTIDE LINKED MEDICINAL AGENTS

A non-enzymatically self cleaving dipeptide element is provided that can be linked to known medicinal agents via an amide bond. The dipeptide will spontaneously be cleaved from the medicinal agent under physiological conditions through a reaction driven by chemical instability. Accordingly, the dipeptide element provides a means of linking various compounds to known medicinal agents wherein the compounds are subsequently released from the medicinal agent after a predetermined time of exposure to physiological conditions. For example, the dipeptide can be linked to an active site of a drug to form a prodrug and/or the dipeptide may comprise a depot polymer to sequester an injectable composition comprising the complex at the point of administration.